Introduction
Cardiac transthyretin (ATTR) amyloidosis is a rarely diagnosed infiltrative cardiomyopathy with an inexorably progressive clinical course and poor prognosis. It is characterized by the relentless deposition and accumulation of fibrillar amyloid deposits in the extracellular space of the myocardium. ATTR amyloid fibrils are composed of either wild-type or variant transthyretin, the latter associated with a multitude of mutations in the transthyretin (TTR) gene. 1, 2 Wild-type ATTR (ATTRwt) amyloidosis is usually diagnosed in elderly males, 3, 4 and mutant ATTR (ATTRm) cardiac amyloidosis is particularly prevalent in certain populations such as individuals of African descent and from North West Ireland in whom the respective pathogenic V122I and T60A TTR variants are present in 4% 5 and 1% 6 of individuals, respectively. Certain TTR variants, such as V30M, which is particularly prevalent in Swedish, Japanese, and Portuguese populations, may result in a clinical phenotype of ATTR amyloidosis that is characterized by predominant autonomic and peripheral polyneuropathy in which the heart is spared. 7 The traditional gold standard for diagnosis of cardiac ATTR amyloidosis is demonstration of cardiac amyloid deposits in an endomyocardial biopsy in the context of a characteristic echocardiogram or cardiac magnetic resonance (CMR) scan. Recently however, cardiac uptake on bone scintigraphy with tracers such as 99m Technetium 3,3-diphosphono-1,2-propanodicarboxylic acid ( 99m Tc-DPD) and pyrophosphate ( 99m Tc-PYP) has been confirmed to have high diagnostic sensitivity and specificity for cardiac ATTR amyloidosis. 8 Rapezzi and colleagues devised a simple four-stage grading system based on the intensity of uptake in the myocardium relative to that in the bones (Perugini grade 0-3). 9 The aim of our study was to determine whether patient stratification by Perugini grade on 99m Tc-DPD scintigraphy has prognostic significance in ATTR amyloidosis, and to further investigate the biological basis for the different 99m Tc-DPD scan appearances across the Perugini grades.
Methods Patients
Six hundred and two patients with ATTR amyloidosis underwent 99m Tc-DPD scintigraphy at the UK National Amyloidosis Centre between 2010 and 2016. Both ATTRwt and ATTRm amyloidosis were diagnosed in accordance with previously published criteria. 8 Patients were managed symptomatically, as previously described. 3 Deaths were recorded by the UK Office for National Statistics (ONS) and death certificate data was obtained from the NHS Health and Social Care Information Centre (HSCIC). 10 Censor date was 5th October 2016.
All patients were managed in accordance with the Declaration of Helsinki and provided informed consent for publication of their data. The study was approved by the Royal Free Hospital ethics committee. Tc-DPD intravenously and imaged 3 hrs later on either a General Electric (GE) Infinia Hawkeye 4 or GE Discovery 670 hybrid gamma camera. Whole body images were acquired at a scan speed of 10 cm/min using low energy high resolution collimators and were immediately followed by a SPECT-CT (single photon emission computed tomography with a low-dose, non-contrast CT scan) of the heart, as previously described. 11 The expected radiation dose from the entire procedure was 6.7 mSv per patient. Intensity of myocardial uptake on planar 99m
Tc-DPD scan was categorized as 0-3 according to the widely used Perugini grading system. 9 Briefly, this comprises: grade 0-no cardiac uptake and normal bone uptake; grade 1-cardiac uptake which is less intense than the bone signal; grade 2-cardiac uptake with intensity similar or greater than bone signal; and grade 3-cardiac uptake with much attenuated or absent bone signal.
Soft tissue to femur ratio was calculated in the whole cohort by placing a line profile region of interest across the mid-thighs on the anterior whole body image and subsequently dividing the number of counts at the level of the skeletal muscle/soft tissue region by those at the adjacent femur level, as previously reported.
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Echocardiography
All patients underwent echocardiography at the UK National Amyloidosis Centre, as previously described. 12 Presence or absence of cardiac ATTR amyloidosis was determined on the basis of consensus criteria, initially established for cardiac AL amyloidosis, 13 with the addition in selected cases of gadolinium enhanced CMR imaging. 14, 15 Briefly, presence of cardiac amyloidosis was defined by positive Congo red histology on endomyocardial biopsy and/or mean left ventricular wall thickness of >12 mm on echocardiography and/or presence of delayed gadolinium enhancement on CMR imaging.
Cardiac magnetic resonance imaging
A subset of 122 patients with cardiac ATTR amyloidosis from the cohort underwent equilibrium contrast CMR imaging within 24 hrs of their Tc-DPD scan, on a 1.5-T clinical scanner (Avanto or Aera, Siemens Healthcare, Erlangen, Germany), reflecting the limited availability of this additional service. Cardiac amyloid burden was estimated by calculation of extracellular volume (ECV), as previously described. 15 Patients were stratified according to Perugini grade on 99m
Tc-DPD scan and cardiac amyloid burden by CMR imaging was compared between groups.
Skeletal muscle histology
Skeletal muscle biopsies were obtained in six of the patients from the cohort. All muscle biopsies were stained with Congo red by the method of Puchtler et al. 16 Amyloid deposits identified in these biopsies were typed immunohistochemically as previously described. Tc-DPD scan and patient survival was compared using the log-rank test. Patient and diseaserelated factors significantly associated with death by univariate analyses to a 0.1 level, were investigated in the whole cohort by Cox proportional hazards regression analysis to establish those that were independently associated with death to a significance level of 0.05 using IBM SPSS Statistics 23 software. ECV and soft tissue to femur ratios were compared between groups by Mann-Whitney U test. patients with ATTRm amyloidosis, the most prevalent variants were V122I (n = 92) and T60A (n = 59), both of which are associated with a phenotype dominated by cardiac amyloidosis. Cardiac ATTR amyloidosis, identified on the basis of echocardiography, histology and/or CMR scan findings was present in a total of 563/602 (94%) patients. Thirty-five patients had V30M-associated ATTR amyloidosis, which is predominantly a neuropathic disease, and in which cardiac involvement is often absent. It is noteworthy that patients with V30M-associated ATTR amyloidosis had lower median LV wall thickness and NT-proBNP values in keeping with this clinical phenotype. Patient demographics for the whole cohort and in each individual cohort at the time of the baseline 99m Tc-DPD scan are shown in Table 1 . Median follow-up from baseline for the whole cohort was 29.6 months during which time 202 patients died. Cause of death in almost all (>95%) patients was from 'progressive amyloidosis', usually associated with pneumonia or end-stage cardiac failure. Tc-DPD scan, was separately compared in three different cohorts of patients; those with ATTRwt amyloidosis (n = 377), those with V122I-associated ATTR amyloidosis (n = 92), and those with T60A-associated ATTR amyloidosis (n = 59). There was no difference in survival on the basis of 99m Tc-DPD scan grade of positivity in any of these patient cohorts (Figure 2A-C) . In 35 patients with V30M-associated ATTR amyloidosis, survival was significantly longer among the 19 patients without cardiac uptake of 99m Tc-DPD, none of whom had evidence of cardiac amyloidosis by consensus criteria, compared to 16 patients with positive 99m Tc-DPD scans (log rank test, P < 0.02).
Results
Patients
Additional factors influencing survival
The following additional factors were significant predictors of mortality in the whole cohort by univariable analyses; age (P < 0.001), 6 min walk test distance (P < 0.001), left ventricular ejection fraction (P = 0.002), Troponin T concentration (P < 0.001), NT-proBNP concentration (P < 0.001), ECOG performance status (P < 0.001), supine systolic blood pressure (P < 0.001), estimated glomerular filtration rate (eGFR) (P < 0.001), and NYHA class (P < 0.001).
The only factors independently associated with mortality in a multivariable Cox proportional hazards model with age, ECOG performance status, left ventricular ejection fraction, Tc-DPD scans, but with considerable overlap between the groups (Figure 3) . Comparison of cardiac amyloid burden between those with a Perugini grade 0 and those with a Perugini grade 2 or 3 99m Tc-DPD scan showed no overlap between the groups and was highly significantly different (Mann Whitney U test, P = <0.0001). 
Soft tissue to femur ratio by 99m Tc-DPD scintigraphy
Discussion and conclusions
The findings presented in this large study of patients with ATTR amyloidosis, 91% of whom had a Perugini grade 2 or 3 Tc-DPD scan is based on attenuation of the bone signal. Whilst the latter has previously been attributed to competitive uptake of 99m Tc-DPD in the heart vs. the bones, we have previously demonstrated on planar whole body imaging that the apparent attenuation of bone signal reflects uptake of tracer in the skeletal muscle and/or soft tissue overlying the bones, 11 further corroborated here by the highly significant increase in soft tissue to femur ratio observed in patients with a grade 3 99m
Tc-DPD scan compared to a
Perugini grade 2 99m
Tc-DPD scan. Amyloid in the soft tissues and muscle has previously been reported as a clinical manifestation of ATTR amyloidosis, 19 and muscle biopsies performed in a small subset of patients in this cohort confirmed skeletal muscle amyloid in all 3 patients with Perugini grade 3 99m
Tc-DPD scans, but none of 3 patients with Perugini grade 1 or 2 99m Tc-DPD scans. Whilst skeletal muscle amyloid deposits may be relatively scanty and of limited clinical significance, the total bulk of skeletal muscle in a patient may easily exceed 25 kg, compared to a typical myocardial mass of less than 0.5 kg. Skeletal muscle amyloid may therefore represent a substantial compartment in terms of localisation of the 99m Tc-DPD tracer, potentially competing with uptake into amyloid in the heart and thereby complicating its quantification by the Perugini grading method. This is also the mechanism by which tracer uptake into the bones is obscured on visualization of planar whole body imaging, resulting in the appearance of a Perugini grade 3 Tc-DPD scans, there was considerable overlap between these groups and no survival difference was detected. Given that <5% of patients in the cohort had Perugini grade 1 99m Tc-DPD scans, the comparison between patients with grade 1 and patients with grades 2 or 3 99m Tc-DPD scans should be interpreted with a degree of caution. Nonetheless, these data serve to re-affirm the diagnostic sensitivity of 99m Tc-DPD scintigraphy for cardiac ATTR amyloidosis, and corroborate previously reported findings which show that presence of cardiac involvement by amyloid among patients with ATTR amyloidosis confers a poor prognosis. 2, 20 It is noteworthy that a substantial proportion of patients (19/28) with Perugini grade 0 99m Tc-DPD scans, none of whom had evidence of cardiac amyloid on either CMR scan or echocardiography, had V30M-associated ATTR amyloidosis and that their median age was 39 years. It is well established that younger V30M-associated ATTR amyloidosis patients often have a phenotype characterized by polyneuropathy without cardiomyopathy. 21 Multivariable analyses on the whole cohort showed that the only independent predictors of mortality were eGFR and ECOG performance status at baseline. In summary, 99m Tc-DPD scintigraphy is exquisitely sensitive for identifying the presence of cardiac ATTR amyloid at the time of diagnosis. Although a Perugini grade 2 or 3 99m Tc-DPD scan has a high diagnostic sensitivity and specificity for cardiac ATTR amyloidosis, it is the presence of cardiac amyloid indicated by abnormal cardiac uptake of 99m Tc-DPD into the heart rather than the Perugini grade of uptake that confers prognostic significance in patients with ATTR amyloidosis. Uptake of tracer into skeletal muscle and soft tissue amyloid deposits is the chief cause of the attenuated bone signal among patients with grade 3 99m Tc-DPD scans. 
